Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
January 23 2023 - 8:00AM
Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage
biopharmaceutical company focused on developing drugs that
meaningfully improve the lives of patients with rare
cardiopulmonary disease, today announced the appointment of Donald
Santel as a member of Aerovate’s Board of Directors. With over 40
years of working in the industry, Mr. Santel brings to Aerovate
extensive experience in building successful pharmaceutical
companies.
"We are excited to welcome Don to Aerovate’s Board of Directors.
Don’s proven track record of leading and building biopharmaceutical
companies from the ground up and taking them through extensive
periods of growth will be invaluable to Aerovate as we continue to
develop AV-101, our novel dry powder inhaled formulation of the
drug imatinib, for the treatment of pulmonary arterial
hypertension, also known as PAH,” said Timothy Noyes, Chief
Executive Officer of Aerovate. “Don’s leadership and counsel will
be extremely beneficial to Aerovate as we endeavor to deliver on
our goal of bringing meaningful therapies to patients with
PAH.”
Mr. Santel currently serves as Chairman of the Board of several
biopharmaceutical companies, including Tentarix Biotherapeutics and
Ocelot Bio, and also served as Chairperson of the Board for Oyster
Point Pharma prior to their acquisition by Viatris in January 2023.
Prior to these roles, he served as Executive Chairman and interim
Chief Executive Officer of Adicet Bio, Inc., a private allogeneic
cell therapy oncology company, through its reverse merger with
resTORbio, Inc. Mr. Santel was also Chief Executive Officer and
board member for Hyperion Therapeutics, Inc., a public
biotechnology company; a co-founder, board member and Chief
Executive Officer for CoTherix, Inc., a biopharmaceutical company
focused on developing therapies for cardiopulmonary disease,
including PAH, and was employed by several medical device
companies, including Cardiac Pathways Corporation (acquired by
Boston Scientific) and Medtronic, Inc. Mr. Santel previously served
on the board of directors and the audit and compensation committees
of Anthera Pharmaceuticals, Inc. and as a director of ChemGenex
Pharmaceuticals, Inc.
“Aerovate continues to broaden its leadership expertise to
advance AV-101 through the clinic,” said Mark Iwicki, Chair of the
Board. “The appointment of Mr. Santel further strengthens the
breadth and depth of the Board’s capabilities, and we look forward
to having Don on the Board as we support the company’s continued
growth.”
“I am thrilled to join the highly accomplished team of PAH
veterans and cardiopulmonary experts at Aerovate,” said Mr. Santel.
“Having seen the unmet need and impact of PAH on patients in my
previous experience, I am encouraged to see new candidates advance
in clinical development. As a part of the next generation of PAH
therapies, Aerovate’s novel AV-101 presents a unique opportunity to
provide meaningful therapeutic innovation in this area of high
unmet medical need.”
About Aerovate Therapeutics, Inc.Aerovate is a
clinical-stage biopharmaceutical company focused on developing
drugs that meaningfully improve the lives of patients with rare
cardiopulmonary disease. Aerovate's initial focus is on advancing
AV-101, its proprietary dry powder inhaled formulation of the drug
imatinib for the treatment of patients with PAH. Learn more at
aerovatetx.com and follow the company on Twitter and LinkedIn.
Available InformationAerovate
announces material information to the public about the Company, its
products and services, and other matters through a variety of
means, including filings with the U.S. Securities and Exchange
Commission (SEC), press releases, public conference calls,
webcasts, the investor relations section of the Company website at
ir.aerovatetx.com, and the Company’s Twitter account @AerovateTx in
order to achieve broad, non-exclusionary distribution of
information to the public and for complying with its disclosure
obligations under Regulation FD.
Cautionary Note Regarding
Forward-Looking StatementsThis press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements can be identified by words such as
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“future,” “goal,” “intend,” “look forward to,” “may,” “plan,”
“potential,” “predict,” “project,” seek,” “strategy,” “should,”
“target,” “will,” “would” and similar expressions regarding future
periods. These forward-looking statements include, but are not
limited to, statements regarding the therapeutic potential and
clinical benefits of AV-101; our business plans and objectives for
AV-101, including expectations regarding timing and success; and
our growth and goals as a company.
Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, those risks and uncertainties related to the
therapeutic potential of AV-101; the expected impact and
contribution of our Board of Driectoprs and executives to our
business; as well as those risks and uncertainties set forth more
fully under the caption “Risk Factors” in our most recent Annual
Report on Form 10-K filed with the SEC and subsequent filings with
the SEC. We caution you not to place undue reliance on any
forward-looking statements, which speak only as of the date they
are made. We disclaim any obligation to publicly update or revise
any such statements to reflect any change in expectations or in
events, conditions or circumstances on which any such statements
may be based, or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements.
Any forward-looking statements contained in this press release
represent our views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent
date.
Media Contactinfo@aerovatetx.com
Investor Contactir@aerovatetx.com
Aerovate Therapeutics (NASDAQ:AVTE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aerovate Therapeutics (NASDAQ:AVTE)
Historical Stock Chart
From Jul 2023 to Jul 2024